At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Brad McGregor, Director of Clinical Research for the Lank Center for Genitourinary Oncology, delivered a talk on “Adjuvant Therapy: Patient Selection and Treatment Options”.
Dr. Brad McGregor spoke about advances in the perioperative setting for clear cell RCC. He explained how prognostic models such as UISS, Leibovich, and ASSURE—once used mainly to predict outcomes are now becoming central to treatment decisions in the era of adjuvant therapy.
He also highlighted the KEYNOTE-564 trial, which showed that pembrolizumab significantly improved disease-free and overall survival for patients with high-risk RCC after surgery. He emphasized that prognostic tools are evolving from being purely educational to practical instruments for risk stratification and guiding personalized treatment, marking an important shift in how clinicians manage high-risk RCC.
Join us in the conversation.